Press Releases

Adds Phase 1 Novel Epilepsy Development Program ROCKVILLE, Md. , Sept. 13, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced

Posted: September 13, 2018

Second Appeal Win against Generic Filers ROCKVILLE, Md. , Sept. 06, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that

Posted: September 6, 2018
Displaying 1 - 10 of 17